Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Acute Promyelocytic Leukemia with FIP1L1-RARA — Variants & evidence · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm
Leukemia
Acute Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia with Genetic Abnormalities
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia with a Variant RARA Rearrangement
Acute Promyelocytic Leukemia with FIP1L1-RARA

Hematologic Malignancy

Acute Promyelocytic Leukemia with FIP1L1-RARA

CI-CAN-00009317Explore in graph →

Hematologic

NCIt: C198839

Overview
Statistics
Survival
Genomics
Variants & evidence
Drugs
Trials
Research
Rankings
Sources & provenance

Variants & evidence

Curated clinical evidence by variant and therapy

Data not yet available

No curated evidence item maps to this entity or its descendants. Evidence comes from CIViC and is displayed with its native level (A–E), direction (supports / does not support) and significance — never collapsed to a verdict.

What CancerIndex knows

Genomics tab
Drugs tab